ALNY Stock Price, News and Analysis
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Market Cap: $44,143,613,480.4
Industry: PHARMACEUTICAL PREPARATIONS
Track ALNY stock with real-time alerts and market analysis
Current Price: $327.36
Alnylam Pharmaceuticals Inc.
$327.36
-0.96%$-3.18
Major market announcement affects tech stocks across all sectors
Earnings report shows significant growth in quarterly revenue
Regulatory changes impact industry outlook for upcoming quarter